Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

OREX 6.35 -0.03 (-0.47%)
price chart
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing therapies to treat obesity, surged higher by as much as 33% after the company reported its third-quarter earnings results and provided an ...
Orexigen Therapeutics rises as European Union review of weight loss drug ...  Fox Business
Orexigen (OREX) Up On Strong Q3 Results  Bidness ETC
Related articles »  
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ, after reporting ...
Stock Insight: Orexigen Therapeutics, Inc. (NASDAQ:OREX)  Markets Wired
Company High Short Interest: Orexigen Therapeutics , Cree Inc  Markets Insider
Related articles »  
Orexigen Therapeutics, Inc. (OREX) Bulls Wager On Sharp Gains
Orexigen Therapeutics, Inc. (NASDAQ:OREX) has surged 3.8% to trade at $5.96, and calls are flying off the shelves at almost nine times the expected intraday clip.
Stock Insight: Orexigen Therapeutics Inc. (NASDAQ:OREX)
[PRNewswire] Orexigen Therapeutics, Inc. (NASDAQ:OREX) (TREND ANALYSIS) announced that management will present a company overview at the Piper Jaffray Healthcare Conference in New York.
Orexigen Therapeutics Short Interest Down 7.9% in November (OREX)  The Legacy
Investor's Alert: Orexigen Therapeutics, Inc.(OREX), KB Home(KBH ...  Techsonian (press release)
Related articles »  
How Bad Is This Delay for Orexigen Therapeutics, Inc?
Orexigen Therapeutics (NASDAQ: OREX ) recently announced that the Food and Drug Administration was delaying an approval decision on the biotech's obesity drug Contrave for three months.
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
In 2011, Orexigen was in a tight race with VIVUS (NASDAQ: VVUS ) and Arena Pharmaceuticals (NASDAQ: ARNA ) to gain FDA approval of the first new obesity drug.
Orexigen Wins US FDA Approval for Weight-Loss Pill  Businessweek
Takeda and Orexigen Announce FDA Approval of Contrave´┐Ż (naltrexone HCI ...  MarketWatch
Related articles »  
Short Interest in Orexigen Therapeutics Declines By 7.9% (OREX)
Orexigen Therapeutics, Inc develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's ...
Related articles »  
Not Even a Weight Loss Drug Could Stop Orexigen Therapeutics, Inc. From ...
Those fears have sparked a flurry of research and development into drugs that could help reduce the risk of type 2 diabetes by helping patients lose weight, including Orexigen Therapeutics' (NASDAQ: OREX ) recently approved Contrave. Yet despite ...
Related articles »  
Orexigen Therapeutics Breaks the Glass Ceiling (ARNA, VVUS, OREX)
If you happened to put Orexigen Therapeutics, Inc. (NASDAQ:OREX) on your watchlist based on my advice from Monday, you can go ahead and put it in your portfolio of you believed in the premise then (and assume all the normal, inherent risks of trading a ...
Closing Bell Highlights: 3M Company (MMM), Orexigen Therapeutics, Inc ...
Orexigen Therapeutics, Inc. (OREX) of the Healthcare sector (Drug Manufacturers - Other) closed the day at $6.38 gaining 7.77%, a change from open of 5.98% with a volume of 3,938,708 shares.